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Amyotrophic lateral sclerosis (ALS) belongs to the group
of motor neuron diseases, in which the degeneration, the
weakness of voluntary muscles, and death of motor neu-
rons gradually spread along disease progression. ALS comes
from Greek language and means “no muscle nourishment”
(“amyotrophic”), “area of the spinal cord where affected nerve
cells are localized” (“lateral”), and “the degeneration and
hardening of the spinal cord” (“sclerosis”). The fundamen-
tal contributions of the celebrated neurologist Jean-Martin
Charcot at the end of the nineteenth century provided the
first description of ALS. His neurological work was based
on the “anatomo-clinical method,” in which he determined
the correlation between clinical signs detected during life
and anatomical lesions seen at death. Nowadays, the patho-
physiological mechanisms that prompt the neurodegener-
ative process in both forms of the disease, familial and
sporadic ALS, still remain to be elucidated. However, there
is growing evidence that the pathogenic process involved in
ALS is multifactorial and includes oxidative stress, glutamate
excitotoxicity, mitochondrial dysfunction, axonal transport
systems, and dysfunction of glial cells, yielding the damage
of critical proteins and organelles in the motor neurons
and muscles and triggering the neurodegeneration. In this
complex scenario, the need for identifying potential biomark-
ers that could make an earlier prognosis and diagnosis of
the disease possible becomes an essential step to finally
decode the molecular basis of ALS and to provide promising
therapeutic strategies.
This special issue provides more in-depth information,
not only considering relevant molecular and plastic features
in ALS but also including accurate reviews focused on
potential biomarkers of the disease in different tissues. More
specifically, the role of two molecular factors, the vascular
endothelial growth factor (VEGF) and the glial cell-derived
neurotrophic factor (GDNF), is described. In particular,
detailed characterization of VEGF in different human tissues
and its connection to a potential therapeutic approach for
ALS is addressed. Regarding GDNF, recent findings could
pave the way for further studies dealing with its receptor,
c-Ret, and its possible connection to the enteric nervous
system in ALS human samples. Following with the molecular
characterization of the disease, the involvement of dorsal root
ganglion sensory neurons under misfolded SOD-1 mediated
neurotoxicity is described in a murine model of ALS. In
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line with the neuronal plasticity in the spinal cord from
G93Amice, neuronal progenitor cells differentiation towards
a neuron-like phenotype under lithium treatment is reported.
A novel 3D mechanoelectrochemical model that can
predict and quantify the impact of immobilized cartilage
from ALS patients suffering a progressive loss of motion is
documented in this issue. Particularly interesting is the use
of neuroimaging techniques to provide an accurate identifi-
cation of potential prognostic and diagnostic biomarkers of
the disease at any stage. In this regard, a detailed review about
neuroimaging studies in ALS, especially magnetic resonance
imaging studies and spinal cord neuroimaging, is presented.
Last but not least, a careful revision of novel biomarkers,
such as aquaporin-4, AQP4, and the inwardly rectifying
potassium channel Kir4.1, and their role in the maintenance
of ion homeostasis at the blood-brain barrier in ALS animal
models and patients is addressed. A more extended revision
focused on a wide-ranging panel of biomarkers in blood is
described based on the different pathological mechanisms
that can contribute to the progression of the disease. Finally,
a general update in ALS focusing on the potential ALS
biomarkers identified along disease progression in animal
models and ALS patients is also included.
We hope that the accurate and updated manuscripts in
this issue will provide not only new insights into the search
of reliable biomarkers but also a starting point for innovative
perspectives in the disease.
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